Published in J Antimicrob Chemother on February 01, 1995
Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev (1995) 7.55
Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother (1996) 3.82
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother (1997) 3.46
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.15
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother (1997) 3.05
Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol (1998) 2.82
Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother (1996) 2.75
Role of the tetraheme cytochrome CymA in anaerobic electron transport in cells of Shewanella putrefaciens MR-1 with normal levels of menaquinone. J Bacteriol (2000) 2.19
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol (2002) 1.83
Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol (2006) 1.63
Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.60
Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates. Front Microbiol (2017) 1.39
rpoB Gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis (2001) 1.35
Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. J Clin Microbiol (2006) 1.31
Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 1.24
Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997). J Clin Microbiol (1999) 1.09
Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin. BMC Microbiol (2009) 1.09
Detection of mutations associated with isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates from Samara Region, Russian Federation. J Clin Microbiol (2004) 1.07
Insusceptibility of members of the class Mollicutes to rifampin: studies of the Spiroplasma citri RNA polymerase beta-subunit gene. Antimicrob Agents Chemother (1996) 1.04
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax (1998) 0.99
Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies. Lung India (2012) 0.94
Detection of rifampin resistance by single-strand conformation polymorphism analysis of cerebrospinal fluid of patients with tuberculosis of the central nervous system. J Clin Microbiol (1997) 0.91
A genome-wide analysis of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis Beijing genotype. Mol Genet Genomics (2013) 0.85
Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother (2001) 0.81
Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn Microbiol Infect Dis (2016) 0.80
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. BMC Infect Dis (2014) 0.79
Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? Front Microbiol (2015) 0.77
Synthesis and structural activity relationship study of antitubercular carboxamides. Int J Med Chem (2014) 0.75
Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil. Mem Inst Oswaldo Cruz (2015) 0.75
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 16.75
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol (1998) 6.59
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother (1994) 6.39
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (2001) 5.52
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet (1993) 4.96
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother (1993) 4.54
Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A (1999) 4.33
Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med (1995) 4.10
Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother (2000) 3.56
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
A novel insertion element from Mycobacterium avium, IS1245, is a specific target for analysis of strain relatedness. J Clin Microbiol (1995) 3.20
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 3.16
Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother (1997) 3.05
Screening of respiratory tract specimens for the presence of Mycobacterium tuberculosis by using the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test. J Clin Microbiol (1994) 2.94
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr (2006) 2.89
Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol (1996) 2.66
Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. Nat Struct Biol (1998) 2.59
Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother (1997) 2.53
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol (1991) 2.47
HIV treatment failure: testing for HIV resistance in clinical practice. Science (1998) 2.46
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol (1997) 2.24
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother (1999) 2.02
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 2.01
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses (2000) 1.82
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet (1998) 1.62
Typing of Pneumocystis carinii f. sp. hominis by single-strand conformation polymorphism of four genomic regions. J Clin Microbiol (1997) 1.59
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther (2009) 1.57
Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy. AIDS (2001) 1.55
Improved performance of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test when 500 instead of 50 microliters of decontaminated sediment is used. J Clin Microbiol (1996) 1.52
Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene (1994) 1.51
Evaluation of the relatedness of strains of Mycobacterium avium using pulsed-field gel electrophoresis. Eur J Clin Microbiol Infect Dis (1995) 1.51
Genotypic characterization of Mycobacterium avium strains recovered from animals and their comparison to human strains. Appl Environ Microbiol (1995) 1.47
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 1.22
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.20
Evaluation of the rpoB gene in rifampicin-susceptible and -resistant Mycobacterium avium and Mycobacterium intracellulare. J Antimicrob Chemother (1994) 1.16
Molecular epidemiology of tuberculosis among HIV-infected persons in Switzerland: a countrywide 9-year cohort study. Swiss HIV Cohort Study. Infection (2000) 1.14
The decaying genome of Mycobacterium leprae. Lepr Rev (2001) 1.11
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.10
Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). Cytokines (1992) 1.10
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol (1995) 1.09
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther (1995) 1.06
Rapid and sensitive single-step radiochemical assay for catechol-O-methyltransferase. J Neurochem (1982) 1.06
Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens (2007) 1.05
Drug resistance in Mycobacterium tuberculosis. Eur Respir J Suppl (1995) 1.04
More on "what's in a name ... "--pragmatism in mycobacterial taxonomy. Int J Tuberc Lung Dis (1998) 1.04
Antiretroviral therapies from the patient's perspective. AIDS Care (2000) 1.04
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit (2001) 1.02
On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl (1988) 0.97
The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates. Genes Immun (2008) 0.97
HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol (1999) 0.96
Polymicrobial fungemia: microbiology, clinical features, and significance. Rev Infect Dis (1989) 0.95
Competitive polymerase chain reaction using an internal standard: application to the quantitation of viral DNA. J Virol Methods (1992) 0.95
Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis (1993) 0.93
Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol (1996) 0.92
Virological and immunological characteristics of HIV treatment failure. AIDS (2000) 0.92
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther (1997) 0.92
Characterization of a novel murine testis-specific serine/threonine kinase. Gene (1994) 0.92
Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol (1987) 0.92
Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS (2001) 0.91
Molecular characterization of the murine syk protein tyrosine kinase cDNA, transcripts and protein. Biochem Biophys Res Commun (1995) 0.90
Survey of urine from transplant recipients for polyomaviruses JC and BK using the polymerase chain reaction. Mol Cell Probes (1991) 0.90
Changes in renal function associated with indinavir. AIDS (1998) 0.89
Molecular techniques in the diagnosis of drug-resistant tuberculosis. Ann Acad Med Singapore (1997) 0.89
Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol (1996) 0.89
Development of a molecular typing method for Pneumocystis carinii sp.f. hominis. J Eukaryot Microbiol (1996) 0.88
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.88
Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med (2008) 0.88
Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry (2000) 0.87
iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochem Biophys Res Commun (1995) 0.86
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS (2001) 0.86
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol (1997) 0.86
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. Open Forum Infect Dis (2015) 0.86
Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol (1997) 0.85
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. Open Forum Infect Dis (2014) 0.85
Intestinal absorption of levodopa in man. Eur J Clin Pharmacol (1983) 0.85
Inteins in mycobacterial GyrA are a taxonomic character. Microbiology (1998) 0.85
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infect Dis (2015) 0.84
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Sci Appl (2000) 0.84
Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J Neurochem (1992) 0.83
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol (1998) 0.83
Efavirenz decreases methadone blood concentrations. AIDS (2000) 0.83
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS (2000) 0.83
Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol (1995) 0.83
Pulsed field gel electrophoresis for mycobacteria. Methods Mol Biol (1998) 0.83
High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease. BMC Infect Dis (2011) 0.83
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol (1987) 0.82
Simultaneous determination of histamine and N alpha-methylhistamine in biological samples by an improved enzymatic single isotope assay. Agents Actions (1985) 0.82
Mycobacterial genome structure. Electrophoresis (1998) 0.81
Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cells. Eur J Pharm Sci (2000) 0.81
HLA and HIV: modeling adaptation to moving targets. Pharmacogenomics J (2003) 0.80